AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02631746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02631746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT04744259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation
Description: A psychological intervention which aims to increase activity and reduce depressive symptoms.
Study NCT04181268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary Intervention
Description: Calcified plaque modification during percutaneous coronary intervention
Study NCT02983916 — intervention group
Intervention type: PROCEDURE
Intervention: Adhesiolysis
Description: Diagnostic laparoscopy or laparotomy with lysis of adhesions.
Study NCT01716923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S-303 Red Blood Cells (RBCs) - Test
Study NCT01716923 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, untreated red blood cells (RBCs) - Control
Study NCT00474383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
Study NCT00474383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
Study NCT02364609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Dimaleate
Description: Given PO
Study NCT02364609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03463538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic capsular release
Description: surgical release of shoulder joint capsule
Study NCT03463538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydro-dilatation
Description: dilatation of shoulder joint capsule using water pressure under local anesthetic
Study NCT02791126 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
Study NCT02791126 — intervention group
Intervention type: OTHER
Intervention: Echocardiogram
Description: For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
Study NCT02598934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
Study NCT01731470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liposomes
Description: Intravesical instillation of liposomes.
Study NCT00669019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Study NCT01974661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COMBIG-DC (ilixadencel)
Description: Allogenic dendrite-cell based therapeutic vaccine
Study NCT01618071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat meals varying in their fatty acid composition
Description: 70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
Study NCT01618071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-fat meals varying in their fatty acid composition
Description: 70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
Study NCT03799354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal strenght training (MST) plus endurance training (ET)
Description: Patients will perform an addictive out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions) consisting of:~1. MST- It will consist of four sets of five repetitions on a leg-press with a focus on the rate of force development during the concentric contraction of the quadriceps from a 90° to legs complete extension. The load will be 85-90% of 1RM. When a patient will be able to perform more than five repetitions in a set, the load will be increased. All strength training will be performed on a seated horizontal leg press.~2. ET - A cycling session will follow the MST and last 40 minutes at constant-load, starting from a load intensity corresponding to patient specific AT. The intensity will be gradually increased with a symptom-based progression.
Study NCT03799354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training (ET)
Description: Patients will perform a usual out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions). They will perform ET by cycling sessions that will last 40 minutes/each at constant-load, starting from a load intensity corresponding to patient specific AT, assessed during the baseline incremental test. The intensity will be gradually increased during the sessions with a symptom-based progression, according to the protocol by Maltais and coworkers. A 3-min warm-up and cool-down will be provided. Heart rate (HR), blood pressure, oxygen pulsoxymetry, and symptoms by Borg CR10 scale will be monitored at the beginning and end of each session.~Out of the training-days, both groups will continue their normal daily living with modest regular activity, as recommended by their physician.
Study NCT01569750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1, Cohort 1
Description: Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
Study NCT01569750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1, Cohort 2
Description: Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
Study NCT01569750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1, Cohort 3
Description: Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
Study NCT02574351 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood draw, breathing test
Description: A blood draw,breathing test will be performed on every participant
Study NCT02394925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal Test Contact lens
Description: Used in a daily wear modality
Study NCT02094547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New infant formula
Description: New infant formula
Study NCT02094547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Description: Standard infant formula
Study NCT02094547 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Breastfeeding
Description: Exclusive breastfeeding or less tan 25% formula intake
Study NCT02785575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HeProCalc algorithm
Description: Heparin and protamine dosage calculated by the algorithm HeProCalc
Study NCT01569750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2, Cohort 1
Description: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
Study NCT01569750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2, Cohort 2
Description: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
Study NCT00833183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL
Description: 80 mg/g cream one administration with incubation for 90 minutes
Study NCT02224352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional neuromuscular electrical stimulation
Study NCT01716091 — intervention group
Intervention type: PROCEDURE
Intervention: irrigation in the peritoneal cavity
Description: irrigation in the peritoneal cavity after uterine wall closed at cesarean
Study NCT02585141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDIPLAST® (aspiration)
Description: The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
Study NCT02585141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: incision
Description: Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
Study NCT02585141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
Study NCT02546778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermosux RF
Description: The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
Study NCT01613807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin LISPRO
Description: Humalog® Mix50/50™ \[50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)\], three times daily at mealtime. Dose determined by blood glucose history.
Study NCT01613807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Long-Acting and Insulin
Description: Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
Study NCT02275845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
Study NCT02275845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control diet
Description: 2000 calories/day diet, with an adequate distribution of carbohydrates during the day
Study NCT02275845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control diet
Description: 2000 calories/day diet, with an adequate distribution of carbohydrates during the day
Study NCT00742014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
Study NCT03618927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily physical activity intervention
Study NCT03159325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Circles
Description: See description in the arm description.
Study NCT04532983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of mesh prosthesis
Description: in the first group mesh was fixed in position with laparoscopic tacks
Study NCT04532983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesh placement without fixation
Description: mesh placement in preperitoneal space without fixation
Study NCT04950387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Based in yoga, common load
Study NCT04306913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: esmolol 250 mg in cardioplegia solution every 25 minutes
Study NCT04306913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Cardioplegic Solution
Description: 15 meq potassium added to cardioplegia solution
Study NCT04306913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Cardioplegic Solution
Description: 15 meq potassium added to cardioplegia solution
Study NCT02629419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Description: Oral lipid nanocrystal formulation of amphotericin B
Study NCT01729091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous stem cell transplant
Study NCT01729091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV
Study NCT01729091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01729091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01729091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01729091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given IV
Study NCT01729091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood-Derived Lymphocyte Therapy
Description: Given IV
Study NCT00888407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBV Screening - Small group educational session
Description: Small group HBV focused discussion with HBV screening resources.
Study NCT00888407 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nutrition - Small group educational session
Description: Small group session with diet \& nutrition focused, topic related resources provided.
Study NCT04145323 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICG microangiography
Description: Indocyanine Green (ICG) is a FDA approved dye which preferentially bind to exposed phospholipids in the membranes of necrotic cells, thus acting as a biomarker for necrotic tissue.
Study NCT03184142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation
Description: Students witness the intimidation of one of their peers (who is an actor) by a professor (also an actor). (see arm description)
Study NCT03184142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Student watch a 15-minute intimidation video (see arm description).
Study NCT03184142 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No intervention. The students suture for 70 minutes
Study NCT02862652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
Study NCT03465085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
Study NCT03465085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptokinase
Description: Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
Study NCT03767400 — intervention group
Intervention type: DEVICE
Intervention: Skin Imaging
Description: Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.
Study NCT03767400 — intervention group
Intervention type: OTHER
Intervention: Facial Cleanser
Description: Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.
Study NCT04125771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diclofenac + HBB with hysteroscopy
Description: Giving Diclofenac + HBB with hysteroscopy
Study NCT04125771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diclofenav + placebo
Description: Giving Diclofenac + placebo with hysteroscopy
Study NCT02587013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type A of uterine repair: In situ
Description: The uterine incision is closed with the uterus within the abdominal cavity
Study NCT02587013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Type B of uterine repair: Exteriorization
Description: The uterine incision is repaired with the exteriorization of the uterus
Study NCT04301700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfullness and relaxation
Description: three arms: mindfullness and relaxation
Study NCT02956122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLASSIA
Description: GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]
Study NCT02956122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone or equivalent steroid
Description: The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
Study NCT02956122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone or equivalent steroid
Description: The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
Study NCT02956122 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Albumin
Description: The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
Study NCT04560777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO-OP intervention
Description: The general structure of the intervention will follow the original key principles of CO-OP, with some adjustments to adapt it to the specificities of the ABI population (14 CO-OP sessions vs 10 in the original protocol).~The global strategy will be taught to the participant at the first session. The following sessions will be consisted of an process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the participant will be experiencing when performing the self-selected tasks. In addition, homework will be assigned to encourage the application and practice of the cognitive strategies discovered during the intervention sessions. Parents will be invited to attend the sessions if it will be possible for them. In any case, the global strategy, as well as the progress of the child, will be explained to the parents.
Study NCT01165164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 115958D (lubricant eye drop)
Description: 1 drop in each eye at bedtime
Study NCT04358614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib 4 MG Oral Tablet
Description: Baricitinib+antiviral therapy administration for 2 weeks
Study NCT04358614 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Baricitinib 4 MG Oral Tablet
Description: Baricitinib+antiviral therapy administration for 2 weeks
Study NCT00874562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
Study NCT00874562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Taken orally mixed with water or orange juice
Study NCT01926197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.